Promedior Initiates Phase 1 Clinical Trial Of PRM-151

Promedior has initiated phase 1 clinical trial of PRM-151, a novel compound in development for the treatment of fibrotic diseases and tissue remodeling.

The phase 1 dose escalation study is designed to evaluate the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of ascending single intravenous doses of PRM-151 in healthy subjects.

Dominick Colangelo, CEO of Promedior, said: “The initiation of the Phase 1 clinical trial of PRM-151 represents an important milestone in the development of Promedior’s novel platform of products for the treatment of fibrotic diseases.

“We believe that PRM-151 has tremendous potential to play an important role in improving patient outcomes across multiple disease indications, he added.